2012
Advances in the Treatment of Metastatic Melanoma: New Immunomodulatory Agents
Sznol M. Advances in the Treatment of Metastatic Melanoma: New Immunomodulatory Agents. Seminars In Oncology 2012, 39: 192-203. PMID: 22484191, DOI: 10.1053/j.seminoncol.2012.01.007.Peer-Reviewed Original ResearchConceptsNew immunomodulatory agentsImmunomodulatory agentsMetastatic melanomaT cell activationT cellsAdverse eventsDendritic cellsClinical activityOngoing phase III trialsRandomized phase III studyCo-inhibitory receptor PD-1Co-stimulatory antibodiesMajor adverse eventsPhase III studyPhase III trialsReceptor PD-1Durable clinical responsesImmune cell subsetsSubsequent clinical trialsParticular T cellsActivated T cellsMechanism of actionAdvanced diseaseClinical responseIII study
2010
Melanoma: A model for testing new agents in combination therapies
Ascierto PA, Streicher HZ, Sznol M. Melanoma: A model for testing new agents in combination therapies. Journal Of Translational Medicine 2010, 8: 38. PMID: 20406483, PMCID: PMC2873374, DOI: 10.1186/1479-5876-8-38.Peer-Reviewed Original ResearchConceptsC-Kit inhibitorsAdvanced melanomaImmune modulatorsIntroduction of interferonNew single agentsMulti-modality treatmentReliable predictive biomarkersSelection of patientsAdoptive cellular therapyAnti-angiogenesis agentsValidation of PatientAdditional molecular targetsImmunologic modulatorsAdvanced diseaseCombination therapyPredictive biomarkersIL-2High success rateIndividual patientsNew agentsSmall molecule inhibitorsPatientsSingle agentResponse rateAnticancer modalities